Production of Authentic SARS-CoV Mpro with Enhanced Activity: Application as a Novel Tag-cleavage Endopeptidase for Protein Overproduction

Journal of Molecular Biology

Volumn 366, Issue 3, 2007, Pages 965-975

  Xue, Xiaoyu ^a,b   Yang, Haitao ^a,b   Shen, Wei ^a   Zhao, Qi ^a   Li, Jun ^a   Yang, Kailin ^a   Chen, Cheng ^a   Jin, Yinghua ^a   Bartlam, Mark ^a,b   Rao, Zihe ^a,b,c  

^a TSINGHUA UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c NANKAI UNIVERSITY   (China)

Author keywords

crystal structure; endopeptidase; fusion protein; main protease; SARS coronavirus

Indexed keywords

HYBRID PROTEIN; PROTEINASE; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITOR INTERACTION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SARS CORONAVIRUS; STRUCTURE ANALYSIS; WILD TYPE;

SARS CORONAVIRUS;

EID: 33846623636     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2006.11.073     Document Type: Article

References (42)

1. Edwards A.M., Arrowsmith C.H., Christendat D., Dharamsi A., Friesen J.D., Greenblatt J.F., and Vedadi M. Protein production: feeding the crystallographers and NMR spectroscopists. Nature Struct. Biol. 7 (2000) 970-972 (Suppl.)
2. Bucher M.H., Evdokimov A.G., and Waugh D.S. Differential effects of short affinity tags on the crystallization of Pyrococcus furiosus maltodextrin-binding protein. Acta Crystallog. sect. D 58 (2002) 392-397
3. Walker P.A., Leong L.E., Ng P.W., Tan S.H., Waller S., Murphy D., and Porter A.G. Efficient and rapid affinity purification of proteins using recombinant fusion proteases. Biotechnology (NY) 12 (1994) 601-605
4. Wang Q.M., Johnson R.B., Cox G.A., Villarreal E.C., and Loncharich R.J. A continuous colorimetric assay for rhinovirus-14 3C protease using peptide p-nitroanilides as substrates. Anal. Biochem. 252 (1997) 238-245
5. Stols L., Gu M., Dieckman L., Raffen R., Collart F.R., and Donnelly M.I. A new vector for high-throughput, ligation-independent cloning encoding a tobacco etch virus protease cleavage site. Protein Expr. Purif. 25 (2002) 8-15
6. Kapust R.B., Tozser J., Fox J.D., Anderson D.E., Cherry S., Copeland T.D., and Waugh D.S. Tobacco etch virus protease: mechanism of autolysis and rational design of stable mutants with wild-type catalytic proficiency. Protein Eng. 14 (2001) 993-1000
7. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1967-1976
8. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348 (2003) 1953-1966
9. Kuiken T., Fouchier R.A., Schutten M., Rimmelzwaan G.F., van Amerongen G., van Riel D., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362 (2003) 263-270
10. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 (2003) 1319-1325
11. Fouchier R.A., Kuiken T., Schutten M., van Amerongen G., van Doornum G.J., van den Hoogen B.G., et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423 (2003) 240
12. Yang H., Xie W., Xue X., Yang K., Ma J., Liang W., et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3 (2005) e324
13. Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., and Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300 (2003) 1763-1767
14. Yang H., Yang M., Ding Y., Liu Y., Lou Z., Zhou Z., et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc. Natl Acad. Sci USA 100 (2003) 13190-13195
15. Xu T., Ooi A., Lee H., Wilmouth R., Liu D., and Lescar J. Structure of the SARS coronavirus main proteinase as an active C2 crystallographic dimer. Acta Crystallog. sect. F 61 (2005) 964-966
16. Tan J., Verschueren K.H., Anand K., Shen J., Yang M., Xu Y., et al. pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J. Mol. Biol. 354 (2005) 25-40
17. Hsu M.-F., Kuo C.-J., Fang J.-M., Shie J.-J., Chang K.-T., Chang H.-C., et al. Understanding the maturation process and inhibitor design of SARS-CoV 3CLpro from the crystal structure of C145A in a product-bound form. J. Biol. Chem. (2005) M502577200
18. Lee T.W., Cherney M.M., Huitema C., Liu J., James K.E., Powers J.C., et al. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. J. Mol. Biol. 353 (2005) 1137-1151
19. Bacha U., Barrila J., Velazquez-Campoy A., Leavitt S.A., and Freire E. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 43 (2004) 4906-4912
20. Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem. 279 (2004) 1637-1642
21. Chou C.Y., Chang H.C., Hsu W.C., Lin T.Z., Lin C.H., and Chang G.G. Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease. Biochemistry 43 (2004) 14958-14970
22. Hsu W.C., Chang H.C., Chou C.Y., Tsai P.J., Lin P.I., and Chang G.G. Critical assessment of important regions in the subunit association and catalytic action of the severe acute respiratory syndrome coronavirus main protease. J. Biol. Chem. 280 (2005) 22741-22748
23. Chen S., Chen L., Tan J., Chen J., Du L., Sun T., et al. Severe acute respiratory syndrome coronavirus 3C-like proteinase N terminus is indispensable for proteolytic activity but not for enzyme dimerization. Biochemical and thermodynamic investigation in conjunction with molecular dynamics simulations. J. Biol. Chem. 280 (2005) 164-173
24. Ziebuhr J. The coronavirus replicase. Curr. Top. Microbiol. Immunol. 287 (2005) 57-94
25. Huang C., Wei P., Fan K., Liu Y., and Lai L. 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry 43 (2004) 4568-4574
26. Kao R.Y., To A.P., Ng L.W., Tsui W.H., Lee T.S., Tsoi H.W., and Yuen K.Y. Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. FEBS Letters 576 (2004) 325-330
27. Blanchard J.E., Elowe N.H., Huitema C., Fortin P.D., Cechetto J.D., Eltis L.D., and Brown E.D. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem. Biol. 11 (2004) 1445-1453
28. Mikkonen M., Soininen H., and Pitkanen A. Distribution of parvalbumin-, calretinin-, and calbindin-D28k-immunoreactive neurons and fibers in the human entorhinal cortex. J. Comp. Neurol. 388 (1997) 64-88
29. Fortin M., and Parent A. Distribution of calretinin, calbindin-D28k and parvalbumin in the hypothalamus of the squirrel monkey. J. Chem. Neuroanat. 14 (1997) 51-61
30. Winsky L., and Kuznicki J. Distribution of calretinin, calbindin D28k, and parvalbumin in subcellular fractions of rat cerebellum: effects of calcium. J. Neurochem. 65 (1995) 381-388
31. Berggard T., Szczepankiewicz O., Thulin E., and Linse S. Myo-inositol monophosphatase is an activated target of calbindin D28k. J. Biol. Chem. 277 (2002) 41954-41959
32. Matthews D.A., Dragovich P.S., Webber S.E., Fuhrman S.A., Patick A.K., Zalman L.S., et al. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl Acad. Sci. USA 96 (1999) 11000-11007
33. Matthews D.A., Smith W.W., Ferre R.A., Condon B., Budahazi G., Sisson W., et al. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 77 (1994) 761-771
34. Copeland R.A. Enzymes. In: Copeland R.A. (Ed). A Practical Introduction to Structure, Mechanism, and Data Analysis. 2nd edit. (2000), Wiley VCH, New York 120-122
35. Hsu M.F., Kuo C.J., Chang K.T., Chang H.C., Chou C.C., Ko T.P., et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J. Biol. Chem. 280 (2005) 31257-31266
36. Lin C.W., Tsai C.H., Tsai F.J., Chen P.J., Lai C.C., Wan L., et al. Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs. FEBS Letters 574 (2004) 131-137
37. Schechter I., and Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophy. Res. Commun. 27 (1967) 157-162
38. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collection in oscillation mode. Methods Enzymol. 276 (1997) 307-326
39. Pozsgay M., Szabo G., Bajusz S., Simonsson R., Gaspar R., and Elodi P. Study of the specificity of thrombin with tripeptidyl-p-nitroanilide substrates. Eur. J. Biochem. 115 (1981) 491-495
40. Smith D.B., and Johnson K.S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 67 (1988) 31-40
41. Chang J.Y. Thrombin specificity. Requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptide substrate. Eur. J. Biochem. 151 (1985) 217-224
42. Cho K., Tanaka T., Cook R.R., Kisiel W., Fujikawa K., Kurachi K., and Powers J.C. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates. Biochemistry 23 (1984) 644-650